Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome - AReMIS

Study identifier:NIS-CFR-BRI-2012/1

ClinicalTrials.gov identifier:NCT01952392

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Study on the prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome

Medical condition

Acute Coronary Syndrome

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

4992

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 01 Oct 2013

Primary Completion Date: 01 Mar 2016

Study Completion Date: 01 Mar 2016

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2017 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Paris, France

Arms	Assigned Interventions
Control group Patients aged 18 years or more with an acute coronary syndrome, agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary	-
Case group Patients aged 18 years or more with a history of acute coronary syndrome (i.e. a recurrent MI after myocardial history or unstable angina), agreed to participate and able to answer an interview in French and/or providing the details of an alternative replier (proxy) if necessary	-

Documents available

CSR_Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com